32952 Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: SBIR/STTR Commercialization 

Readiness Pilot (CRP) Program. 

Date: July 15, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Allen Richon, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7892, Bethesda, MD 20892, 301–379– 

9351, allen.richon@nih.hhs.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

HIV Coinfections and HIV Associated 

Cancers Study Section. 

Date: July 15, 2021. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jingsheng Tuo, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3196, 

Bethesda, MD 20892, 301–451–5953, tuoj@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Fellowship: 

Infectious Diseases and Immunology Panel C. 

Date: July 15–16, 2021. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shahrooz Vahedi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 810G, 

Bethesda, MD 20892, (301) 496–9322, 

vahedis@mail.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

HIV Immunopathogenesis and Vaccine 

Development Study Section. 

Date: July 15–16, 2021. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shiv A. Prasad, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5220, 

MSC 7852, Bethesda, MD 20892, 301–443– 

5779, prasads@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Reproductive Biology. 

Date: July 16, 2021. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Yunshang Piao, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

Bethesda, MD 20892, (301) 402–8402, 

piaoy3@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Infectious 

Diseases and Immunology Research 

Enhancement Review. 

Date: July 19, 2021. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Liangbiao Zheng, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

MSC 7808, Bethesda, MD 20892, 301–996– 

5819, zhengli@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Human Complex Mental Function. 

Date: July 19, 2021. 

Time: 1:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Pamela Jeter, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 10J08, 

Bethesda, MD 20892, (301) 435–2591, 

pamela.jeter@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in infectious diseases 

vaccines, therapeutics and vector biology. 

Date: July 20, 2021. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Gagan Pandya, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, RM 3200, 

MSC 7808, Bethesda, MD 20892, 301–435– 

1167, pandyaga@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 17, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13184 Filed 6–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Substance Abuse 

Treatment; Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Treatment 

(CSAT) National Advisory Council 

(NAC) will meet on August 12, 2021, 

1:00 p.m.–4:30 p.m. (EDT). 

The meeting is open to the public and 

will include consideration of minutes 

from the SAMHSA CSAT NAC meeting 

of March 31, 2021; an update on CSAT 

activities; a discussion with SAMHSA 

leadership; and discussion of recovery 

and recovery support. Interested 

persons may present data, information, 

or views, orally or in writing, on issues 

pending before the Council. Written 

submissions should be forwarded to the 

contact person on or before August 6, 

2021. Oral presentations from the public 

will be scheduled at the conclusion of 

the meeting. Individuals interested in 

making oral presentations must notify 

the contact person on or before August 

6, 2021. Five minutes will be allotted for 

each presentation. 

The meeting will be conducted via 

WebEx and telephone only, and 

registration is required to participate 

during this me. To attend virtually, or 

to obtain the call-in number and access 

code, submit written or brief oral 

comments, or request special 

accommodations for persons with 

disabilities, please register on-line at 

http://snacregister.samhsa.gov/ 

MeetingList.aspx, or communicate with 

the CSAT National Advisory Council 

Designated Federal Officer; Tracy Goss 

(see contact information below). 

Meeting information and a roster of 

Council members may be obtained by 

accessing the SAMHSA Committee 

website at http://www.samhsa.gov/ 

about-us/advisory-councils/csatnational-advisory-council or by 

contacting the CSAT National Advisory 

Council Designated Federal Officer. 

Council Name: SAMHSA’s Center for 

Substance Abuse Treatment National 

Advisory Council. 

Date/Time/Type: August 12, 2021, 

1:00 p.m.–4:30 p.m. EDT, OPEN. 

Place: SAMHSA, 5600 Fishers Lane, 

Rockville, Maryland 20857. 

Contact: Tracy Goss, Designated 

Federal Officer, CSAT National 

Advisory Council, 5600 Fishers Lane, 

Rockville, Maryland 20857 (mail), 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices 32953 

1The Protecting and Securing Chemical Facilities 

from Terrorist Attacks Act of 2014 (also known as 

the CFATS Act of 2014, Pub. L. 113–254) codified 

the CFATS program into the Homeland Security 

Act of 2002. See 6 U.S.C. 621 et seq., as amended 

by Public Law 116–136, Sec. 16007 (2020). 

2The recordkeeping burden for facilities under 

CFATS is accounted for by CISA under the CSAT 

Information Collection No. 1670–0007. 

Telephone: (240) 276–0759, Email: 

tracy.goss@samhsa.hhs.gov. 

Dated: June 16, 2021. 

Carlos Castillo, 

Committee Management Officer, SAMHSA. 

[FR Doc. 2021–13132 Filed 6–22–21; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

[Docket No. CISA–2021–0003] 

Notice of Request for Revision of a 

Currently Approved Information 

Collection for the Chemical Facility 

Anti-Terrorism Standards (CFATS) 

AGENCY: Cybersecurity and 

Infrastructure Security Agency, DHS. 

ACTION: 30-Day notice and request for 

comments; revision of Information 

Collection Request: 1670–0014. 

Authority: 6 U.S.C. 621–629. 

SUMMARY: The Infrastructure Security 

Division (ISD) within the Cybersecurity 

and Infrastructure Security Agency 

(CISA) is issuing a 60-day notice and 

request for comments to revise 

Information Collection Request (ICR) 

1670–0014. CISA will submit the ICR to 

the Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the Paperwork 

Reduction Act of 1995. DHS previously 

published this information collection 

request (ICR), in the Federal Register, 

on Monday, March 23, 2021 at 86 FR 

15490 for a 60-day public comment 

period. No comments was/were 

received by DHS. To access and review 

all documents related to this 

information collection, please visit the 

Federal eRulemaking Portal site at 

http://www.regulations.gov and enter 

Docket Number CISA–2021–0003 in the 

search box. The purpose of this notice 

is to allow an additional 30 days for 

public comments. 

DATES: Comments are encouraged and 

will be accepted until August 23, 2021. 

ADDRESSES: You may submit comments, 

identified by docket number CISA– 

2021–0003 through the Federal 

eRulemaking Portal available at http://

www.regulations.gov. Follow the 

instructions for submitting comments. 

Instructions: All comments received 

via https://www.regulations.gov will be 

posted to the public docket at https://

www.regulations.gov, including any 

personal information provided. 

Do not submit comments that include 

trade secrets, confidential commercial 

or financial information, Chemicalterrorism Vulnerability Information 

(CVI), Protected Critical Infrastructure 

Information (PCII), or Sensitive Security 

Information (SSI) directly to the public 

regulatory docket. Contact the 

individual listed in the FOR FURTHER

INFORMATION CONTACT section below 

with questions about comments 

containing protected information. CISA 

will not place comments containing 

protected information in the public 

docket and will handle them in 

accordance with applicable safeguards 

and restrictions on access. Comments 

containing protected information will be 

held in a separate file to which the 

public does not have access and CISA 

will place a note in the public docket 

documenting receipt of the comment. If 

CISA receives a request to examine or 

copy this information, CISA will treat it 

as any other request under the Freedom 

of Information Act (FOIA), 5 U.S.C. 552, 

and the Department’s FOIA regulation 

found in part 5 of Title 6 of the Code 

of Federal Regulations (CFR). 

FOR FURTHER INFORMATION CONTACT: 

Lona Saccomando, 703–235–5263, 

CISARegulations@cisa.dhs.gov. 

SUPPLEMENTARY INFORMATION: The 

CFATS Program identifies chemical 

facilities of interest and regulates the 

security of high-risk chemical facilities 

through a risk-based approach. The 

CFATS Program is authorized under the 

Protecting and Securing Chemical 

Facilities from Terrorist Attacks Act of 

2014 1 or ‘‘CFATS Act of 2014’’. CISA 

collects necessary information through 

1670–0014 to implement CFATS. 

CISA’s Methodology in Estimating the 

Burden for the Request for 

Redetermination 

This instrument collects information 

to support a facility’s request for 

redetermination of high-risk which 

CISA is obligated to perform pursuant to 

the CFATS Act of 2014. The collection 

of information may be concurrent with 

a facility’s submission of a Top-Screen 

pursuant to 6 CFR 27.210(d) or collected 

after CISA reviews a Top-Screen that 

reflects material modifications made by 

the facility. This instrument authorizes 

CISA to collect both the reason for the 

redetermination as well as supporting 

documentation. 

CISA is proposing minor revisions to 

the instrument that reflect the passage of 

the Cybersecurity and Infrastructure 

Security Act of 2018, 6 U.S.C. 651–74, 

such as updating the Agency name to 

conform with the Agency’s new 

designation as CISA, as well as a clearer 

description of the scope of the 

instrument. The scope of this 

instrument remains unchanged. 

Number of Respondents 

The current information collection 

estimated that 625 respondents would 

submit a request for a Request for 

Redetermination annually. Based on 

data collected between CY 2018–2020, 

215 respondents, on average, submitted 

a Request for Redetermination annually. 

Because of the historical pattern of 

lower submissions over the past three 

years, CISA proposes to decrease the 

estimated number of respondents from 

625 to 250 respondents. CISA will retain 

the number of responses per respondent 

of 1.0. 

Estimated Time per Respondent 

In the current information collection, 

the estimated time per respondent to 

prepare and submit a Request for 

Redetermination is 0.25 hours (15 

minutes). CISA continues to believe this 

is a reasonable burden estimate for this 

instrument. 

Annual Burden Hours 

The annual burden hours for a 

Request for Redetermination is [0.25 

hours × 250 respondents × 1 response 

per respondent], which equals 62.5 

hours. 

Total Capital/Startup Burden Cost 

CISA provides access to CSAT free of 

charge and assumes that each 

respondent already has computer 

hardware and access to the internet for 

basic business needs. Therefore, there 

are no annualized capital or start-up 

costs incurred by chemical facilities of 

interest or high-risk chemical facilities 

for this information collection. 

Total Recordkeeping Burden 

There are no recordkeeping burden 

costs incurred by chemical facilities of 

interest or high-risk chemical facilities 

for this information collection.2

Total Annual Burden Cost 

CISA assumes that Site Security 

Officers (SSOs) are responsible for 

submitting a Request for 

Redetermination. For the purpose of this 

notice, CISA maintains this assumption. 

Therefore, to estimate the total annual 

burden, CISA multiplied the annual 

burden of 62.5 hours by the average 

hourly wage rate of SSOs which is 


jbell on DSKJLSW7X2PROD with NOTICES